William (Bill) Hyun

Scribe Biosciences is an early-stage company pioneering technologies to accelerate immunotherapy discoveries through linked functional and genomic profiling of single-cell interactions.

Fluent BioSciences, an Illumina company, is a biotechnology company with a mission to accelerate the understanding of biology and disease through simple, cost effective and scalable solutions for every laboratory from research to the clinic. Fluent’s breakthrough Pre-templated Instant Partitions (PIPseq™) technology enables near-instantaneous self-assembly of individual cells or molecules into millions of uniform partitions without the need for complex instrumentation or expensive consumables. This powerful platform enables extremely sensitive and unbiased preparation of proteins and nucleic acids for a broad range of discovery and disease applications including single-cell RNA sequencing (scRNA-Seq).

Akadeum Life Sciences® has developed a next generation platform that solves long-standing problems across cell therapy and other research, diagnostic and therapeutic markets. The proprietary buoyant microbubble technology platform addresses the need for high cell quality, scalability, time and workflow that current magnetic particle-based products commonly used in cell therapy manufacturing and research can’t address. The Company has several GMP grade and Clinical Ready kits to enable each stage of cell therapy manufacturers pipeline. Harnessing the microbubble capability, the Alerion™ Microbubble Cell Separation System enables cell isolation from tens of billions of cells in apheresis material in under an hour, significantly expanding capacity of manufacturers. Akadeum is currently working with some of the largest corporations and forward-thinking leaders in the industry. The power of the Akadeum microbubble platform is an elegant and easy-to-use technology that can enable faster, more accurate, and scalable workflows to improve human health. Better Isolations. Healthier Cells.

Slingshot Biosciences is working on an overlooked but ubiquitous problem in healthcare that has a tremendous impact on a variety of patient outcomes: the lack of consistent reference material for cell-based assays. The company’s cell mimics represent a new way to use control material in the workflow, whether for instrument manufacturing, assay setup, and validation or as a manufacturing QC control. Synthetic cell mimics provide a new opportunity for precise, biologically-relevant, and cost-effective controls to aid many healthcare and research efforts globally. Learn more at slingshotbio.com

Mission Bio is a company of passionate people dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics. In 2014, the company was spun out of Adam Abate’s lab for high-throughput biology at the University of California, San Francisco (UCSF). Mission Bio’s precision genomics platform is based on the pioneering droplet microfluidics work of Abate and his team. Our mission is to help researchers and clinicians unlock single-cell biology to enable the discovery, development, and delivery of precision medicine. Visit missionbio.com to learn more.

Newbridge Media is a holding company of publishing operations. It maintains two independent business lines: Digital Press International (dpi.com), a news agency, and The Ten Leaders Cooperative, a 5,000 member promotional program for experienced, equity-owning professionals in the law, medicine and finance. Newbridge Media was founded in February 2002 in Fort Lee, N.J. and its businesses and brands were launched in June of that year. Since 2007 DPI.com has been among few digital news operations to report an operating profit. Newbridge Media's primary office today is located in Reston, VA. Newbridge Media's principal shareholder is Stephen E. Clark, former publisher of Bergen County (NJ) Newspapers, which was acquired by the holding company of The Bergen Record in July 2001. Mr. Clark reports to an independent board.

Scribe Biosciences is an early-stage company pioneering technologies to accelerate immunotherapy discoveries through linked functional and genomic profiling of single-cell interactions.

Fluent BioSciences, an Illumina company, is a biotechnology company with a mission to accelerate the understanding of biology and disease through simple, cost effective and scalable solutions for every laboratory from research to the clinic. Fluent’s breakthrough Pre-templated Instant Partitions (PIPseq™) technology enables near-instantaneous self-assembly of individual cells or molecules into millions of uniform partitions without the need for complex instrumentation or expensive consumables. This powerful platform enables extremely sensitive and unbiased preparation of proteins and nucleic acids for a broad range of discovery and disease applications including single-cell RNA sequencing (scRNA-Seq).

Genoa Ventures invests in early-stage companies innovating at the convergence of biology and technology. Visionary startups developing innovative life science technologies with outsized potential often struggle to raise capital from traditional funders. These companies are typically multi-disciplinary (e.g. genomics + optics + microfluidics + big data) and/or market-making, and dont neatly fit most VC’s patterns and boxes. Genoa Ventures stands in this gap. Genoa Ventures uniquely combines an appetite for technology-driven, “category-defying” opportunities in life sciences with the domain expertise and operational experience necessary to select and nurture the best bio-based companies early, before most other investors. We take the time to understand the science and technology, applications and markets, and to help these companies achieve their full potential. We believe in the enormous and relatively untapped possibilities of life science technologies and discoveries applied to realms outside of healthcare, and in the unbounded potential of the entrepreneurial visionaries who will lead us in realizing these possibilities.

Akadeum Life Sciences® has developed a next generation platform that solves long-standing problems across cell therapy and other research, diagnostic and therapeutic markets. The proprietary buoyant microbubble technology platform addresses the need for high cell quality, scalability, time and workflow that current magnetic particle-based products commonly used in cell therapy manufacturing and research can’t address. The Company has several GMP grade and Clinical Ready kits to enable each stage of cell therapy manufacturers pipeline. Harnessing the microbubble capability, the Alerion™ Microbubble Cell Separation System enables cell isolation from tens of billions of cells in apheresis material in under an hour, significantly expanding capacity of manufacturers. Akadeum is currently working with some of the largest corporations and forward-thinking leaders in the industry. The power of the Akadeum microbubble platform is an elegant and easy-to-use technology that can enable faster, more accurate, and scalable workflows to improve human health. Better Isolations. Healthier Cells.

Mission Bay Capital LLC uses capital and expertise to help entrepreneurs emerging from the University of California change the world. We begin with the conviction that more of the creativity of the University of California can directly benefit society. Universities have an obligation to meet public needs for new sources of energy, new solutions for patients, and ultimately the formation of whole new industries. MBC will help launch companies that meet these needs. Our success will redress social challenges, replenish future funds, and ultimately build a research and educational endowment for QB3 (California Institute for Quantitative Biosciences) to drive the development of the next generation of innovations.